Indication
Treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL) who have been previously treated with a Bruton’s tyrosine kinase inhibitor (BTKi).
Medicine details
- Medicine name:
- pirtobrutinib (Jaypirca)
- SMC ID:
- SMC2901
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 01 September 2026